The Norwegian diagnostics company Genetic Analysis is launching AInsight, a platform intended to help healthcare professionals interpret results from the company's GA-map Dysbiosis Test for analysis of the gut microbiome. The system uses an AI model connected to the company's own knowledge database to generate structured interpretation reports. The goal is to simplify clinical use and enable higher testing volumes in laboratories. "We are pleased to present GA-map Dysbiosis Test AInsight as part of our efforts to make clinically validated microbiome diagnostics easier to implement in routine healthcare. By simplifying the interpretation of microbiome data, we aim to support broader use of GA-map Dysbiosis Test and enable laboratories to scale up testing more efficiently," says CEO Ronny Hermansen in a comment. No financial details are provided.